IL-18-induced cancer immunosuppression Edited Precis: IL-18 suppresses the crucial role of natural killer cells (NK cells) in supporting tumor immunosurveillance, with implications for clinical strategies to reverse this mechanism of tumoral immune escape.
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Introduction
Cancer progression constitutes one of the best-characterized pathological conditions in which tolerance is actively induced. Tumors employ several mechanisms to avoid or actively suppress anti-cancer immune responses (1) (2) . Tumor progression subverts the adaptive arm of antitumor immune responses, either directly by compromising T cell functions or indirectly by inhibiting antigen-presenting cells (3) . The secretion by tumor cells of soluble factors (such as IL-6, transforming growth factor-β, vascular endothelium growth factor, macrophage-colony stimulating factor, and indoleamine 2, 3-dioxygenase) can directly block T cell proliferation, promote T cell apoptosis or render tumor cells resistant against T cell attack (4) . The tumor microenvironment can also release IL-23 which is a key NK cell immunosuppressant promoting metastases dissemination of otherwise NK cell-controlled cancers (5) .
Driven by clinical observations linking elevated serum levels of IL-18 with defective NK cell functions (6) (7) and the potential role of tumor derived-IL-18 in cell autonomous tumor progression (8) (9) , we investigated the potential immunosuppressive effects of IL-18 in NK cell-controlled tumors (10-11). We found that IL-18 could upregulate PD-1 expression on NK cells and facilitated metastases dissemination of NK cell-dependent tumors in a PD-1-dependent manner. Depletion or neutralization of IL-18 produced by tumor cells markedly stimulated NK cell -mediated immunosurveillance against cancer.
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Results and Discussion

Low dosing of rIL-18 promotes metastases dissemination
The cell-autonomous protumorigenic effects of endogenous IL-18 have been described in B16F10 melanoma where IL-18 induced adhesiveness of melanoma cells to sinusoidal endothelium, thereby facilitating metastatic dissemination (12) . Since B16F10 metastatic spreading is controlled by NK cells (10), we investigated the mechanisms by which rIL-18 could facilitate tumor progression. We compared different schedules of recombinant mouse of rIL-18 promoted an immunosuppressive microenvironment (significant downregulation of CCR7, Fas, upregulation of IL-10, trend towards a reduction in CXCR3, CD3ε, CD4, CD8, Pfr, CD28, CD40, STAT1) ( Fig. 1D ,E). These data underscore the capacity of low doses of rIL-18 to favour tumor progression of B16F10 metastases.
The source of the immunosuppressive IL-18 is the tumor cell
Next, we determined whether tumor cells may spontaneously secrete bioactive IL-18. Mature (18kDa) bioactive IL-18 was detected in B16F10 and various tumor cell lysates (CT26, P815, RMA and RMAS) by immunoblotting ( Fig In IL-18R -/-or MyD88 -/-mice, the dissemination of B16F10 metastases was markedly reduced, suggesting that B16F10 progression was dependent on the IL-18R/MyD88 signalling pathway of the host (Fig. 2C ). It is noteworthy that upon inoculation of transplantable tumors (B16F10) and in spontaneous melanomas arising in RET transgenic mice (expressing the RET proto-oncogene driven by the metallothionein promoter) (16) , the serum levels of IL-18 were markedly increased by 10 days (premortem) and at 12 months respectively (Suppl. Fig. 1D , E), in the same ranges as those obtained with 2x rIL-18 scheduling (Fig. 1C ). Next, we used saturating amounts of IL-18 binding protein (IL-18BP), a naturally occurring IL-18 antagonist (17) , that successfully compromised tumor progression in two NK cell controlled-lung metastases models (11) Research. Fig. 2D , upper and lower panels). IL-18 neutralization by IL-18BP did not cause tumor regression in the absence of NK1.1 + cells, suggesting that IL-18 modulated NK cell functions ( Fig. 2E ). Therefore, IL-18 produced by tumor cells could subvert the NKmediated anti-tumor host defense.
IL-18 upregulates PD-1 expression on mature NK cells while the pro-tumorigenic activity of IL-18 depends on PD-1 receptors
PD-1 is one of the major checkpoints downregulating T cell functions in tumor beds.
Recently, myeloma associated-human NK cells were reported to express PD-1 that may cause their exhaustion (18) . Therefore, we examined PD-1 expression on T and NK cells in high doses of IL-18 often combined with IL-2 or IL-12 (8, (19) (20) . Cytokine doses and schedules have been discussed in the context of pathogenesis and cancer therapy and molecules such as IL-2 or IL-10 have led to opposite biological outcomes depending on their cellular targets and/or their mode of delivery (rev. in (21) (22) . In patients with cancer, increased IL-18 serum levels accompany tumor progression and have a negative prognostic impact (9) . In the absence of Th1-like cytokines, IL-18 alone accelerates tumor progression (23) , in part through cell autonomous effects on cancer and endothelial cells (23) (24) . In In vivo IL-18 neutralization. IL-18BP was kindly provided by Pr. C. Dinarello (Denver, USA) (17) . At day 0, 3x10 5 B16F10 or CT26 tumor cells were injected iv into C57Bl/6 or BALC/c mice respectively. Mice received 20 μg of IL-18BP (or saline buffer) ip daily from day 0 to day 8 with or without depleting anti-NK1.1 Ab (300 µg injected ip on day 0, 3, 6, 9).
Anti-PD-1 antibody was injected ip (250 μg/mice) at day 0, 1, 3, 6, 9. Immunoblot and bioassay as in A. but using B16F10 transfected with control siRNA (siRNA Co) or two different IL-18-depleting siRNAs (siRNA #1, #2) (upper and middle panels).
Enumeration of lung metastases after inoculation of B16F10 transfected with various siRNA
